Intelligence Profile
Research Papers
Research Papers and Clinical Trials
The research on cagrilintide has primarily focused on its use in combination with semaglutide (called CagriSema) for treating type 2 diabetes and obesity, with several major clinical trials completed in 2026.
Key Clinical Trials
The most significant evidence comes from the REIMAGINE clinical trial program, which includes two large Phase 3 studies published in The Lancet Diabetes & Endocrinology. REIMAGINE 1 examined CagriSema in adults with type 2 diabetes inadequately controlled on diet and exercise alone, while REIMAGINE 2 directly compared the combination therapy against semaglutide or cagrilintide used individually. Both studies were randomized, double-blind, placebo-controlled trials, though specific sample sizes are not provided in the available evidence.
Additional Phase 3 trials have been completed comparing CagriSema to tirzepatide (NCT06221969) and examining the combination against individual components and placebo (NCT06065540). A Phase 2 study (NCT04982575) also evaluated the cagrilintide-semaglutide combination in people with type 2 diabetes.
Systematic Reviews and Meta-Analyses
Two major systematic reviews published in 2026 have included cagrilintide in broader analyses of weight management medications. A BMJ systematic review and network meta-analysis examined comparative effects of drugs for adults with overweight or obesity, while an Annals of Internal Medicine living systematic review assessed benefits and harms of pharmacologic treatments for the American College of Physicians.
Mechanism of Action Research
Recent research published in Nature Metabolism has provided insights into how cagrilintide works at the cellular level. Studies have created a cross-species atlas of the dorsal vagal complex, identifying neural pathways that mediate cagrilintide's effects on energy balance. Companion research has pinpointed specific cellular locations where cagrilintide acts.
Device Usability
A usability study published in the Journal of Diabetes Science and Technology evaluated the CagriSema dual-chamber pen delivery device, examining ease of use, learning, and convenience in adults with overweight, obesity, or type 2 diabetes.
Ongoing and Future Research
Current research includes a Phase 1 study investigating CagriSema's effects on muscle health (NCT07527195) and a planned Phase 3 trial in children and adolescents with type 2 diabetes (NCT07282613).
The evidence base for cagrilintide appears robust for type 2 diabetes applications, though specific outcome data, sample sizes, and detailed results from these studies would be needed to fully assess efficacy and safety profiles.